Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer

被引：1
|
作者：
Ko, R. [1 ]
Oizumi, S. [2 ]
Mizugaki, H. [3 ]
Fujita, Y. [2 ]
Harada, T. [4 ]
Takashina, T. [5 ]
Igawa, S. [6 ]
Watanabe, K. [7 ]
Hotta, T. [8 ]
Minemura, H. [9 ]
Saeki, S. [10 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Resp Med, Tokyo, Japan
[2] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[4] Jcho Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[5] Iwamizawa Municipal Gen Hosp, Iwamizawa, Japan
[6] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan
[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[8] Shimane Univ, Fac Med, Izumo, Shimane, Japan
[9] Fukushima Med Univ, Pulm Med, Fukushima, Japan
[10] Kumamoto Univ, Kumamoto, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Afatinib; Adverse events; Elderly patients;
D O I：
10.1016/j.jtho.2019.08.1187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-36
引用
收藏
页码：S568 / S568
页数：1
相关论文
共 50 条
  • [1] Phase II trial of afatinib in elderly patients over 75 years of age withEGFR mutation positive non-small cell lung cancer
    Watanabe, Kageaki
    Oizumi, Satoshi
    Mizugaki, Hidenori
    Fujita, Yuka
    Harada, Toshiyuki
    Takashina, Taichi
    Igawa, Satoshi
    Ko, Ryo
    Hotta, Takamasa
    Minemura, Hiroyuki
    Saeki, Sho
    Yagishita, Shigehiro
    Hamada, Akinobu
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [2] Phase II trial of afatinib in elderly patients over 75 years of age with EGFR mutation positive NSCLC
    Nakahara, Y.
    Oizumi, S.
    Mizugaki, H.
    Fujita, Y.
    Harada, T.
    Takashina, T.
    Ko, R.
    Watanabe, K.
    Hotta, T.
    Minemura, H.
    Saeki, S.
    Yagishita, S.
    Hamada, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    [J]. LUNG CANCER, 2016, 91 : S22 - S22
  • [4] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
    Minegishi, Yuji
    Yamaguchi, Ou
    Sugawara, Shunichi
    Kuyama, Shoichi
    Watanabe, Satoshi
    Usui, Kazuhiro
    Mori, Masahide
    Hataji, Osamu
    Nukiwa, Toshihiro
    Morita, Satoshi
    Kobayashi, Kunihiko
    Gemma, Akihiko
    [J]. BMC CANCER, 2021, 21 (01)
  • [5] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
    Yuji Minegishi
    Ou Yamaguchi
    Shunichi Sugawara
    Shoichi Kuyama
    Satoshi Watanabe
    Kazuhiro Usui
    Masahide Mori
    Osamu Hataji
    Toshihiro Nukiwa
    Satoshi Morita
    Kunihiko Kobayashi
    Akihiko Gemma
    [J]. BMC Cancer, 21
  • [6] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
    Hisashi Tanaka
    Kageaki Taima
    Yoshihito Tanaka
    Masamichi Itoga
    Yoshiko Ishioka
    Hideyuki Nakagawa
    Keisuke Baba
    Yukihiro Hasegawa
    Shingo Takanashi
    Sadatomo Tasaka
    [J]. Medical Oncology, 2018, 35
  • [7] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
    Tanaka, Hisashi
    Taima, Kageaki
    Tanaka, Yoshihito
    Itoga, Masamichi
    Ishioka, Yoshiko
    Nakagawa, Hideyuki
    Baba, Keisuke
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    [J]. MEDICAL ONCOLOGY, 2018, 35 (03)
  • [8] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [9] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Noro, R.
    Igawa, S.
    Bessho, A.
    Hirose, T.
    Tsuneo, S.
    Nakashima, M.
    MInato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Iihara, H.
    Naoki, K.
    Okamoto, H.
    Kubota, K.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S872 - S873
  • [10] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Igawa, S.
    Noro, R.
    Kubota, K.
    Naoki, K.
    Bessho, A.
    Hirose, T.
    Shimokawa, T.
    Nakashima, M.
    Minato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Lihara, H.
    Okamoto, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1400
12345